Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Lymphoid 1

Conditions

Hemophilia A 2Lymphoma, Follicular 1

Interventions

emicizumab 4Factor VIII 2ziprasidone 1recombinant FVIIa 1anti-inhibitor coagulant complex 1Zolpidem 1Warfarin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Spironolactone 1Sevelamer 1Rocuronium 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1Nifedipine 1Nafcillin 1Molindone 1Methylprednisolone 1Lurasidone Hydrochloride 1Labetalol 1Haloperidol 1Fosfomycin 1Clozapine 1Ciprofloxacin 1Cidofovir 1Cefepime 1Bosentan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hemophilia A × Factor VIII × Clear all
NCT02847637 2022-11-16

HAVEN 3

Hoffmann-La Roche

Phase 3 Completed
152 enrolled 46 charts 1 FDA
Classical hematology

Hemophilia A

NCT00037544 2008-04-22

Study Evaluating ReFacto AF in Severe Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Classical hematologyLymphoid

Hemophilia A, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡